An extreme new multiple sclerosis treatment has been shown to end the disease in its tracks hinting at the possibility of a cure.In a 24 person clinical trial based in Canada one person who was previously confined to a wheelchair enabled to live a normal life again after receiving the multiple sclerosis treatment.The new multiple sclerosis treatment was actually discovered by accident by a team at the Ottawa Hospital Research Institute in Canada through their work with patients diagnosed with both leukemia and multiple sclerosis.One way of tackling the cancer is by extracting bone marrow cells, killing off the remaining immune cells then injecting the bone marrow (once purged of cancer) back into the body to repopulate the immune system.
It turns out this immune system ‘reboot’ is also very advantageous at fighting MS. The disease causes the immune system to attack the protective coating that shields nerve cells in the brain or spinal cord and nervous system. And after noticing the positive results on the condition in leukaemia patients, the researchers decided to trial the new technique just on Multiple sclerosis patients, to try to flush out the immune system and effectively start again.The treatment is designed to stop the progress of MS but in many cases it is actually reversing the progress of the disease suggesting that the nervous system can sometimes repair itself after MS takes hold or reports Clare Wilson for New Scientist
The trial began in 2000, and overall, 17 of the 24 people involved in the study saw their MS terminate or reversed.It’s not an easy treatment to undergo, because of some rather dramatic and debilitating side effects, and it’s currently only being offered to those with severe MS – patients who are essentially left without a functioning immune system for a period of time. That said, its potential is huge if doctors can figure out how to make it safer.”Everyone is hesitating to use the ‘c word’, but these patients are cured,” senior scientist Michael Rudnicki of the Ottawa Health Research Institute in Canada, who wasn’t directly involved in the research, told Vox.